<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05075538</url>
  </required_header>
  <id_info>
    <org_study_id>IJB-COVID-001</org_study_id>
    <secondary_id>2021-003710-39</secondary_id>
    <nct_id>NCT05075538</nct_id>
  </id_info>
  <brief_title>COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2</brief_title>
  <acronym>I-SPARC</acronym>
  <official_title>COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jules Bordet Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial aims to measure the humoral and adaptive immune response in patients with cancer&#xD;
      diagnosis undergoing mRNA vaccination against SARS-CoV-2 and assess its efficacy in&#xD;
      preventing COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Humoral immune response against SARS-CoV-2 after the second dose of a mRNA anti-SARS-CoV-2 vaccine (Baseline assessment)</measure>
    <time_frame>6 months (+/- 4 weeks) after the second dose</time_frame>
    <description>Rate of humoral immune response against SARS-CoV-2 at 6 months (+/- 4 weeks) after the second dose of a mRNA anti-SARS-CoV-2 vaccine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Humoral immune response against SARS-COV-2</measure>
    <time_frame>at 6 months (+/- 4 weeks) after the baseline assessment or at 6 months (+/- 4 weeks) after the boost with the third dose if administered until 12 months (+/- 4 weeks) after the second dose per local / national health policy guidelines.</time_frame>
    <description>Rate of humoral immune response against SARS-COV-2 at 6 months (+/- 4 weeks) after the baseline assessment or at 6 months (+/- 4 weeks) after the boost with the 3rd dose if administered until 12 months (+/- 4 weeks) after the 2nd dose per local / national health policy guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of humoral immune response against SARS-COV-2, by underlying malignant disease</measure>
    <time_frame>6 months (+/- 4 weeks) after the 2nd dose; and 6 months (+/- 4 weeks) after baseline assessment or 6 months (+/- 4 weeks) after the boost with the 3rd dose if administered until 12 months (+/- 4 weeks) after the 2nd dose per local / national health po</time_frame>
    <description>Rate of humoral immune response against SARS-COV-2, by underlying malignant disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of humoral immune response against SARS-COV-2 by cohort</measure>
    <time_frame>6 months (+/- 4 weeks) after the 2nd dose; and 6 months (+/- 4 weeks) after baseline assessment or 6 months (+/- 4 weeks) after the boost with the 3rd dose if administered until 12 months (+/- 4 weeks) after the 2nd dose per local / national health po</time_frame>
    <description>Rate of humoral immune response against SARS-COV-2 by cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of asymptomatic subjects with SARS-CoV-2 positive test during the study</measure>
    <time_frame>during the study</time_frame>
    <description>Rate of asymptomatic subjects with SARS-CoV-2 positive test, confirmed COVID-19 or severe COVID-19 infection with onset at least 14 days after the 2nd dose in subjects who had been without serologic or virological evidence of SARS-CoV-2 infection up to 14 days after the 2nd dose.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of humoral immune response against SARS-COV-2 before and after the third dose</measure>
    <time_frame>within 2 weeks before 3rd dose and at 2 weeks after 3rd dose (+/- 3 days), if administered by until 12 months (+/- 4 weeks) after the 2nd dose per local/national health policy guidelines.</time_frame>
    <description>Rate of humoral immune response against SARS-COV-2 at pre- (within 2 weeks before 3rd dose) and post-boosting (at 2 weeks after 3rd dose, +/- 3 days) with the 3rd dose, if administered by until 12 months (+/- 4 weeks) after the 2nd dose per local/national health policy guidelines.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in the levels of circulating cytokines/chemokines and the balance or differentiation/activation status of lymphocyte subpopulations and their association with anti-SARS-CoV-2 antibodies</measure>
    <time_frame>i) 6 months (+/- 4 weeks) after the 2nd dose; and ii) if a 3rd dose of the vaccine is administered until 12 months (+/- 4 weeks) after the 2nd dose per local / national health policy guidelines; at pre- (within 2 weeks before 3rd dose), post-boosting (at</time_frame>
    <description>Changes in the levels of circulating cytokines/chemokines and the balance or differentiation/activation status of lymphocyte subpopulations and their association with anti-SARS-CoV-2 antibodies</description>
  </other_outcome>
  <enrollment type="Anticipated">525</enrollment>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Spikevax</intervention_name>
    <description>Third dose as per national guidelines</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comirnaty</intervention_name>
    <description>Third dose as per national guidelines</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  ECOG performance status ≤ 2&#xD;
&#xD;
          -  Must have histologically or cytologically confirmed cancer diagnosis (invasive solid&#xD;
             tumour or haematological malignancy)&#xD;
&#xD;
               -  currently undergoing active systemic cancer treatment (such as chemotherapy,&#xD;
                  immunotherapy, targeted agents, endocrine therapy) in non-metastatic setting or&#xD;
                  in metastatic setting (1st line therapy at the time of 1st dose of the&#xD;
                  anti-SARS-CoV-2 mRNA vaccine)&#xD;
&#xD;
               -  or currently undergoing follow-up after confirmed cancer complete remission&#xD;
                  without active cancer treatment for the last 12 months&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
          -  Received 2nd dose of mRNA platform vaccination against SARS-CoV-2 as per local&#xD;
             guidelines within 6 months (maximum until 6 months and 3 weeks) prior to registration.&#xD;
&#xD;
          -  Urine pregnancy test negative for all female subjects of childbearing potential within&#xD;
             7 days prior to subject enrolment.&#xD;
&#xD;
          -  Signed Informed Consent form (ICF) obtained prior to any study related procedure.&#xD;
&#xD;
          -  Subject is willing and able to comply with the protocol for the duration of the study&#xD;
             including treatment and scheduled visits and examinations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known pregnant and/or lactating women.&#xD;
&#xD;
          -  Subject with a significant medical, neuro-psychiatric, or surgical condition,&#xD;
             currently uncontrolled by treatment, which, in the principal investigator's opinion,&#xD;
             may interfere with completion of the study.&#xD;
&#xD;
          -  Subjects with active diagnosis of acute leukaemia.&#xD;
&#xD;
          -  Subjects treated with bone marrow transplant &lt; 90 days before received vaccination&#xD;
             against SARS-CoV-2.&#xD;
&#xD;
          -  Subjects with a known history of HIV infection.&#xD;
&#xD;
          -  COVID-19 infection in the last 28 days before receiving first dose of vaccination&#xD;
             against SARS-CoV-2 and up to subject enrolment.&#xD;
&#xD;
          -  Subjects receiving prolonged and/or high doses of systemic immunosuppressive therapies&#xD;
             including corticosteroids during the last 28 days before receiving first dose of&#xD;
             vaccination against SARS-CoV-2 and up to subject enrolment.&#xD;
&#xD;
          -  Subjects who, for any reason, did not receive the 2nd dose of the anti-SARS-CoV-2 mRNA&#xD;
             vaccine.&#xD;
&#xD;
          -  Subjects that received the 3rd dose of anti-SARS-CoV-2 mRNA vaccine prior to study&#xD;
             entry.&#xD;
&#xD;
          -  Subject that received any dose of non-mRNA anti-SARS-CoV-2 vaccine platform.&#xD;
&#xD;
          -  Known prior severe hypersensitivity to anti-SARS-CoV-2 mRNA vaccines or any component&#xD;
             in its formulations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Evandro DE AZAMBUJA, MD PhD</last_name>
    <phone>+3225413662</phone>
    <email>evandro.azambuja@bordet.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tabatha Delsaute</last_name>
    <phone>+3225413662</phone>
    <email>tabatha.delsaute@bordet.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Angela Loizidou, MD</last_name>
      <email>angela.loizidou@bordet.be</email>
    </contact>
    <investigator>
      <last_name>Angela Loizidou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunity</keyword>
  <keyword>mRNA</keyword>
  <keyword>vaccination</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19</keyword>
  <keyword>COVID19</keyword>
  <keyword>Spikevax</keyword>
  <keyword>Comirnaty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

